Targacept to Host Conference Call Today at 10:00 a.m. on GlaxoSmithKline Product Development Alliance
Winston-Salem, North Carolina
July 27, 2007
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), announced that it will conduct a conference call and audio webcast today at 10:00 a.m. Eastern Daylight Time regarding the company’s product development alliance with GlaxoSmithKline, which was announced earlier this morning. Participants from Targacept will include J. Donald deBethizy, Ph.D., President and Chief Executive Officer; Alan A. Musso, Vice President and Chief Financial Officer; and Jeffrey P. Brennan, Vice President, Business and Commercial Development. Mark Strobeck, Vice President, Drug Discovery Transactions, GlaxoSmithKline, will also participate.
The conference call may be accessed by dialing 866-831-6272 for domestic participants and 617-213-8859 for international callers (reference passcode 57641976). A replay of the conference call may be accessed through August 10, 2007 by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers (reference passcode 67912991).
A live webcast of the conference call will be accessible from the Investor Relations page of Targacept's website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on Targacept's website for at least two weeks following the call.
About Targacept
Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics, a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept’s product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer’s disease and cognitive deficits in schizophrenia, pain and depression and anxiety disorders, and multiple preclinical programs. Targacept is located in Winston-Salem, North Carolina.
Contacts:
Alan Musso, VP and CFO
Targacept, Inc.
Tel: (336) 480-2186
Email: alan.musso@targacept.com
Michelle Linn
Linnden Communications
Tel: (508) 419-1555
Email: linnmich@comcast.net
Back to Newsroom